Report shows significant variation in EU access to new meds

24 June 2024

New reports published by the European Federation of Pharmaceutical Industries and Associations (EFPIA) highlight ongoing disparities in terms of access to medicines.

The trade federation for Europe’s drugmakers said the average time to patient access is 531 days, with significant variations ranging from 126 days in Germany to 804 days in Poland.

The report highlights the degree of variability between countries, with people in some places waiting over six times longer than those in a neighboring region to receive the same treatments.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical